Nestmedic, a Polish telemedicine and digital health start-up, is preparing to launch on the market a mobile cardiotocography (CTG) device, billed as the world’s first comprehensive telemedical solution for fetal monitoring.
The product – called Pregnabit - is currently undergoing final tests and its commercialisation is expected to take place later this year.
CTG is a standard test usually done in the final trimester of pregnancy to monitor the baby’s heart rate. At the moment, CTG systems - large stationary devices – are available in hospitals and clinics, and frequent visits to such places often cause unnecessary stress and discomfort as well as requiring considerable expenditure of time, but with Pregnabit, women will be able to take CTG examinations at home.
The solution – which includes the mobile CTG device and a related service (call centre) – will be offered to private healthcare, i.e. gynaecologists, small and large clinic networks, midwives and birthing schools.
Nestmedic will first introduce it on the Polish market and the company says it has the ambition to be a global pioneer and leader in the mobile CTG market for so-called “physiological” pregnancies, which represent approximately 80% of the total.
The size of this market in Poland is 300,000 patients per year and more than 2.7 million CTG examinations every year, the company notes.
Nestmedic’s founder Patrycja Wizinska-Socha was named Poland’s best young innovator for 2016 by the MIT Technology Review.